Indivumed and University of Rochester's Expanded Collaborative Efforts in Cancer Therapy Discoveries

Indivumed and the University of Rochester Medical Center Strengthen Their Collaboration for Cancer Therapy Discovery

Introduction

Indivumed, a leading biotechnology company focused on precision oncology, is thrilled to announce the expansion of its collaboration with the prestigious Wilmot Cancer Institute at the University of Rochester Medical Center (URMC). This partnership aims to enhance patient-centered cancer research and the development of novel therapeutics, thus promising a brighter future in cancer treatment.

Overview of the Collaboration

The updated collaboration focuses on integrating Indivumed’s standardized clinical and tissue data collection methods with URMC’s renowned capabilities in high-quality biomaterials and clinical data. By adhering to stringent operational standards, the partnership ensures that the precious biological samples are collected and processed efficiently, with ischemia times minimized to under ten minutes – a critical factor for maintaining sample integrity.

The Role of Indivumed

Indivumed's innovative platform is founded on meticulously obtained surgical tissue samples and comprehensive clinical data. This resource serves as a foundation for advancing patient-specific oncological research and drug development. The collaboration's principal objective is to create well-characterized patient-derived tumor models (PDTMs) from these samples. These models encompass classical cell cultures, spheroids, and organoids, which, when coupled with comprehensive datasets, support advances in identifying, validating, screening ligands, and drug-target development for cancer treatment.